Vanguard Group Inc Aridis Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.16 - $0.4 $62,233 - $155,583	-388,959 Reduced 74.07%	136,197 $29,000
Q1 2023 May 15, 2023	BUY	$0.31 - $1.5 $217 - $1,054	703 Added 0.13%	525,156 $162,000
Q4 2022 Feb 10, 2023	BUY	$0.81 - $1.18 $268 - $390	331 Added 0.06%	524,453 $618,000
Q1 2022 May 13, 2022	BUY	$1.33 - $2.59 $22,324 - $43,473	16,785 Added 3.31%	524,122 $922,000
Q4 2021 Feb 14, 2022	BUY	$2.0 - $3.65 $675,600 - $1.23 Million	337,800 Added 199.25%	507,337 $1.18 Million
Q3 2021 Nov 12, 2021	BUY	$3.55 - $7.49 $34,048 - $71,836	9,591 Added 6.0%	169,537 $624,000
Q2 2021 Aug 13, 2021	BUY	$5.3 - $7.4 $847,713 - $1.18 Million	159,946 New	159,946 $1.18 Million

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.